Imugene Research Development vs Selling General Administrative Analysis

IMU Stock

0.04 0 2.56%

Imugene financial indicator trend analysis is infinitely more than just investigating Imugene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Imugene is a good investment. Please check the relationship between Imugene Research Development and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Research Development vs Selling General Administrative

Research Development vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Imugene Research Development account and Selling General Administrative. At this time, the significance of the direction appears to have totally related.

The correlation between Imugene's Research Development and Selling General Administrative is 0.99. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Imugene, assuming nothing else is changed. The correlation between historical values of Imugene's Research Development and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Imugene are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Research Development i.e., Imugene's Research Development and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Selling General Administrative

Most indicators from Imugene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 47.3 M in 2024. Issuance Of Capital Stock is likely to gain to about 57.5 M in 2024

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	203.4K	190.3K	3.3M	3.5M
Net Interest Income	71.9K	1.9M	4.0M	4.2M

Reconciled Depreciation Net Interest Income

Imugene fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Inventory
Total Assets		0.04	0.67	0.72	0.99	0.85	0.96	-0.98	-0.84	0.85	0.99	0.89	0.64	0.99	0.97	0.89	0.93	0.69	-0.97	0.73	0.84	0.99	0.71	0.88	0.96	-0.76
Short Long Term Debt Total	0.04		0.49	0.47	-0.04	0.36	0.13	-0.02	-0.41	0.37	0.04	-0.11	-0.39	0.05	0.11	-0.01	0.12	0.27	-0.16	0.45	0.37	0.07	0.46	-0.15	0.26	0.13
Other Current Liab	0.67	0.49		0.99	0.57	0.95	0.82	-0.56	-0.96	0.89	0.59	0.7	0.46	0.6	0.73	0.68	0.74	0.9	-0.72	0.99	0.95	0.64	1.0	0.65	0.85	-0.44
Total Current Liabilities	0.72	0.47	0.99		0.63	0.97	0.86	-0.62	-0.98	0.93	0.65	0.74	0.49	0.66	0.78	0.72	0.79	0.9	-0.77	1.0	0.97	0.69	1.0	0.69	0.89	-0.49
Total Stockholder Equity	0.99	-0.04	0.57	0.63		0.78	0.93	-0.99	-0.77	0.79	0.99	0.87	0.63	0.99	0.95	0.86	0.9	0.61	-0.95	0.64	0.77	0.99	0.62	0.86	0.91	-0.77
Property Plant And Equipment Net	0.85	0.36	0.95	0.97	0.78		0.94	-0.76	-0.98	0.97	0.78	0.83	0.57	0.79	0.9	0.81	0.88	0.87	-0.86	0.97	1.0	0.82	0.96	0.79	0.95	-0.61
Current Deferred Revenue	0.96	0.13	0.82	0.86	0.93	0.94		-0.91	-0.93	0.91	0.93	0.9	0.7	0.93	0.96	0.86	0.91	0.79	-0.95	0.86	0.94	0.95	0.85	0.88	0.98	-0.67
Net Debt	-0.98	-0.02	-0.56	-0.62	-0.99	-0.76	-0.91		0.76	-0.77	-1.0	-0.8	-0.59	-1.0	-0.93	-0.8	-0.86	-0.55	0.96	-0.62	-0.75	-0.99	-0.61	-0.79	-0.91	0.71
Retained Earnings	-0.84	-0.41	-0.96	-0.98	-0.77	-0.98	-0.93	0.76		-0.94	-0.79	-0.8	-0.52	-0.79	-0.87	-0.8	-0.87	-0.88	0.87	-0.98	-0.98	-0.82	-0.97	-0.76	-0.96	0.58
Accounts Payable	0.85	0.37	0.89	0.93	0.79	0.97	0.91	-0.77	-0.94		0.8	0.8	0.53	0.8	0.91	0.8	0.87	0.82	-0.88	0.93	0.97	0.83	0.92	0.76	0.94	-0.63
Cash	0.99	0.04	0.59	0.65	0.99	0.78	0.93	-1.0	-0.79	0.8		0.81	0.59	1.0	0.94	0.81	0.87	0.57	-0.97	0.65	0.78	1.0	0.64	0.8	0.92	-0.71
Non Current Assets Total	0.89	-0.11	0.7	0.74	0.87	0.83	0.9	-0.8	-0.8	0.8	0.81		0.69	0.81	0.91	0.97	0.93	0.85	-0.81	0.76	0.82	0.83	0.71	1.0	0.87	-0.82
Non Currrent Assets Other	0.64	-0.39	0.46	0.49	0.63	0.57	0.7	-0.59	-0.52	0.53	0.59	0.69		0.6	0.61	0.57	0.5	0.47	-0.61	0.49	0.57	0.6	0.49	0.68	0.59	-0.41
Cash And Short Term Investments	0.99	0.05	0.6	0.66	0.99	0.79	0.93	-1.0	-0.79	0.8	1.0	0.81	0.6		0.94	0.81	0.87	0.58	-0.97	0.66	0.78	1.0	0.65	0.8	0.93	-0.71
Net Receivables	0.97	0.11	0.73	0.78	0.95	0.9	0.96	-0.93	-0.87	0.91	0.94	0.91	0.61	0.94		0.92	0.96	0.74	-0.93	0.79	0.89	0.96	0.77	0.89	0.96	-0.81
Common Stock Total Equity	0.89	-0.01	0.68	0.72	0.86	0.81	0.86	-0.8	-0.8	0.8	0.81	0.97	0.57	0.81	0.92		0.97	0.85	-0.79	0.74	0.8	0.83	0.69	0.97	0.87	-0.92
Common Stock Shares Outstanding	0.93	0.12	0.74	0.79	0.9	0.88	0.91	-0.86	-0.87	0.87	0.87	0.93	0.5	0.87	0.96	0.97		0.83	-0.86	0.8	0.86	0.89	0.76	0.92	0.93	-0.89
Non Current Liabilities Total	0.69	0.27	0.9	0.9	0.61	0.87	0.79	-0.55	-0.88	0.82	0.57	0.85	0.47	0.58	0.74	0.85	0.83		-0.67	0.92	0.87	0.62	0.88	0.83	0.81	-0.64
Other Stockholder Equity	-0.97	-0.16	-0.72	-0.77	-0.95	-0.86	-0.95	0.96	0.87	-0.88	-0.97	-0.81	-0.61	-0.97	-0.93	-0.79	-0.86	-0.67		-0.77	-0.86	-0.97	-0.76	-0.79	-0.96	0.63
Total Liab	0.73	0.45	0.99	1.0	0.64	0.97	0.86	-0.62	-0.98	0.93	0.65	0.76	0.49	0.66	0.79	0.74	0.8	0.92	-0.77		0.97	0.69	0.99	0.71	0.89	-0.51
Property Plant And Equipment Gross	0.84	0.37	0.95	0.97	0.77	1.0	0.94	-0.75	-0.98	0.97	0.78	0.82	0.57	0.78	0.89	0.8	0.86	0.87	-0.86	0.97		0.81	0.97	0.78	0.95	-0.59
Total Current Assets	0.99	0.07	0.64	0.69	0.99	0.82	0.95	-0.99	-0.82	0.83	1.0	0.83	0.6	1.0	0.96	0.83	0.89	0.62	-0.97	0.69	0.81		0.68	0.82	0.95	-0.72
Short Term Debt	0.71	0.46	1.0	1.0	0.62	0.96	0.85	-0.61	-0.97	0.92	0.64	0.71	0.49	0.65	0.77	0.69	0.76	0.88	-0.76	0.99	0.97	0.68		0.66	0.88	-0.46
Intangible Assets	0.88	-0.15	0.65	0.69	0.86	0.79	0.88	-0.79	-0.76	0.76	0.8	1.0	0.68	0.8	0.89	0.97	0.92	0.83	-0.79	0.71	0.78	0.82	0.66		0.84	-0.84
Common Stock	0.96	0.26	0.85	0.89	0.91	0.95	0.98	-0.91	-0.96	0.94	0.92	0.87	0.59	0.93	0.96	0.87	0.93	0.81	-0.96	0.89	0.95	0.95	0.88	0.84		-0.69
Inventory	-0.76	0.13	-0.44	-0.49	-0.77	-0.61	-0.67	0.71	0.58	-0.63	-0.71	-0.82	-0.41	-0.71	-0.81	-0.92	-0.89	-0.64	0.63	-0.51	-0.59	-0.72	-0.46	-0.84	-0.69

Click cells to compare fundamentals

Imugene Account Relationship Matchups

Imugene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	65.2M	71.8M	147.6M	197.1M	151.4M	159.0M
Short Long Term Debt Total	69.3K	271.0K	673.4K	553.5K	1.5M	1.6M
Other Current Liab	1.8M	3.6M	2.7M	3.6M	22.4M	23.5M
Total Current Liabilities	2.9M	4.5M	7.4M	6.1M	29.3M	30.8M
Total Stockholder Equity	59.8M	65.0M	138.7M	189.6M	118.3M	124.2M
Property Plant And Equipment Net	155.6K	466.0K	862.8K	683.0K	1.7M	1.8M
Current Deferred Revenue	390.6K	738.3K	1.3M	1.6M	1.9M	2.0M
Net Debt	(30.0M)	(29.2M)	(99.2M)	(152.6M)	(91.6M)	(87.0M)
Retained Earnings	(47.3M)	(65.7M)	(103.5M)	(141.4M)	(289.8M)	(275.3M)
Accounts Payable	1.0M	759.7K	4.5M	2.3M	6.0M	6.3M
Cash	30.1M	29.5M	99.9M	153.2M	93.1M	97.8M
Non Current Assets Total	30.7M	35.5M	33.8M	31.4M	38.4M	40.3M
Cash And Short Term Investments	30.1M	29.5M	99.9M	153.2M	94.5M	99.3M
Net Receivables	4.2M	6.7M	12.8M	12.1M	12.6M	13.2M
Common Stock Shares Outstanding	4.1B	4.7B	5.6B	6.3B	7.1B	7.4B
Liabilities And Stockholders Equity	65.2M	71.8M	147.6M	197.1M	151.4M	159.0M
Non Current Liabilities Total	2.5M	2.3M	1.5M	1.4M	3.8M	4.0M
Other Stockholder Equity	(45.5M)	(1.0)	(127.3M)	(173.0M)	(155.7M)	(147.9M)
Total Liab	5.4M	6.8M	8.9M	7.4M	33.1M	34.8M
Property Plant And Equipment Gross	155.6K	718.9K	1.3M	1.0M	2.6M	2.8M
Total Current Assets	34.5M	36.3M	113.8M	165.7M	113.0M	118.7M
Accumulated Other Comprehensive Income	14.3M	17.6M	11.4M	16.7M	37.8M	39.7M
Short Term Debt	60.9K	106.0K	184.2K	191.1K	912.5K	958.1K
Intangible Assets	30.5M	34.9M	32.7M	30.5M	34.1M	35.8M
Common Stock	92.8M	113.1M	230.8M	314.4M	370.3M	388.8M
Other Liab	2.5M	2.2M	987.1K	990.6K	1.1M	1.1M
Net Tangible Assets	29.3M	30.1M	106.0M	159.1M	183.0M	192.2M
Long Term Investments	80.6K	115.2K	252.4K	217.6K	2.4M	2.5M
Property Plant Equipment	155.6K	466.0K	862.8K	683.0K	614.7K	645.4K
Other Current Assets	194.1K	170.1K	1.1M	401.6K	5.9M	6.2M
Long Term Debt Total	8.4K	165.0K	489.3K	362.4K	326.2K	462.4K
Net Invested Capital	59.8M	65.0M	138.7M	188.4M	118.3M	85.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Imugene Stock Analysis

When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC